JP2020522244A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522244A5 JP2020522244A5 JP2019565348A JP2019565348A JP2020522244A5 JP 2020522244 A5 JP2020522244 A5 JP 2020522244A5 JP 2019565348 A JP2019565348 A JP 2019565348A JP 2019565348 A JP2019565348 A JP 2019565348A JP 2020522244 A5 JP2020522244 A5 JP 2020522244A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide according
- polynucleotide
- utr
- seq
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091033319 polynucleotide Proteins 0.000 claims 16
- 239000002157 polynucleotide Substances 0.000 claims 16
- 102000040430 polynucleotide Human genes 0.000 claims 16
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 3
- 108020003589 5' Untranslated Regions Proteins 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000002105 nanoparticle Substances 0.000 claims 3
- 101000893559 Homo sapiens Amylo-alpha-1,6-glucosidase Proteins 0.000 claims 2
- 241000723792 Tobacco etch virus Species 0.000 claims 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 2
- 229940045145 uridine Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100040894 Amylo-alpha-1,6-glucosidase Human genes 0.000 claims 1
- 208000032008 Glycogen storage disease due to glycogen debranching enzyme deficiency Diseases 0.000 claims 1
- 206010053250 Glycogen storage disease type III Diseases 0.000 claims 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 1
- 108091036066 Three prime untranslated region Proteins 0.000 claims 1
- 241000269368 Xenopus laevis Species 0.000 claims 1
- XSWXHOQMWXTMEH-QOCHGBHMSA-N [(Z)-non-2-enyl] 4-[2-(dimethylamino)ethylsulfanylcarbonyl-(4-oxo-4-pentadecan-8-yloxybutyl)amino]butanoate Chemical compound CCCCCCCC(CCCCCCC)OC(=O)CCCN(CCCC(=O)OC\C=C/CCCCCC)C(=O)SCCN(C)C XSWXHOQMWXTMEH-QOCHGBHMSA-N 0.000 claims 1
- RGAIHNZNCGOCLA-ZDSKVHJSSA-N [(Z)-non-2-enyl] 8-[2-(dimethylamino)ethylsulfanylcarbonyl-[8-[(Z)-non-2-enoxy]-8-oxooctyl]amino]octanoate Chemical compound CCCCCC\C=C/COC(=O)CCCCCCCN(CCCCCCCC(=O)OC\C=C/CCCCCC)C(=O)SCCN(C)C RGAIHNZNCGOCLA-ZDSKVHJSSA-N 0.000 claims 1
- 150000003838 adenosines Chemical class 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000004543 glycogen storage disease III Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000012096 transfection reagent Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023038257A JP2023075248A (ja) | 2017-05-31 | 2023-03-13 | 糖原病ｉｉｉ型のための治療薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513350P | 2017-05-31 | 2017-05-31 | |
| US62/513,350 | 2017-05-31 | ||
| PCT/US2018/035477 WO2018222926A1 (en) | 2017-05-31 | 2018-05-31 | Therapeutics for glycogen storage disease type iii |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023038257A Division JP2023075248A (ja) | 2017-05-31 | 2023-03-13 | 糖原病ｉｉｉ型のための治療薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020522244A JP2020522244A (ja) | 2020-07-30 |
| JP2020522244A5 true JP2020522244A5 (enExample) | 2021-07-26 |
| JP7284101B2 JP7284101B2 (ja) | 2023-05-30 |
Family
ID=64456114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565348A Active JP7284101B2 (ja) | 2017-05-31 | 2018-05-31 | 糖原病ｉｉｉ型のための治療薬 |
| JP2023038257A Pending JP2023075248A (ja) | 2017-05-31 | 2023-03-13 | 糖原病ｉｉｉ型のための治療薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023038257A Pending JP2023075248A (ja) | 2017-05-31 | 2023-03-13 | 糖原病ｉｉｉ型のための治療薬 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11377643B2 (enExample) |
| EP (1) | EP3630964B1 (enExample) |
| JP (2) | JP7284101B2 (enExample) |
| KR (1) | KR102636537B1 (enExample) |
| CN (1) | CN110719954B (enExample) |
| AR (1) | AR112706A1 (enExample) |
| AU (1) | AU2018278315B2 (enExample) |
| BR (1) | BR112019025224A2 (enExample) |
| CO (1) | CO2019013332A2 (enExample) |
| ES (1) | ES3048960T3 (enExample) |
| MX (1) | MX2019014412A (enExample) |
| TW (1) | TWI794237B (enExample) |
| WO (1) | WO2018222926A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| US10383952B2 (en) | 2016-12-21 | 2019-08-20 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| KR102636537B1 (ko) | 2017-05-31 | 2024-02-15 | 울트라제닉스 파마수티컬 인코포레이티드 | 글리코겐 축적 질환 유형 iii에 대한 치료제 |
| CA3122080A1 (en) | 2018-12-06 | 2020-06-11 | Arcturus Therapeutics, Inc. | Compositions and methods for treating ornithine transcarbamylase deficiency |
| CN110314407A (zh) * | 2019-08-01 | 2019-10-11 | 山东新希望六和集团有限公司 | 一种脂肪快速提取装置 |
| WO2021067598A1 (en) | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| IT202000003371A1 (it) * | 2020-02-19 | 2021-08-19 | Enea Agenzia Naz Per Le Nuove Tecnologie Lenergia E Lo Sviluppo Economico Sostenibile | Composto per il trattamento di una glicogenosi |
| EP4114470A4 (en) | 2020-03-03 | 2024-04-17 | Arcturus Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY |
| JP2023517644A (ja) | 2020-03-09 | 2023-04-26 | アークトゥラス・セラピューティクス・インコーポレイテッド | コロナウイルスワクチン組成物及び方法 |
| MX2023001109A (es) | 2020-07-27 | 2023-04-24 | Anjarium Biosciences Ag | Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas. |
| US12178921B2 (en) | 2020-08-14 | 2024-12-31 | Arcturus Therapeutics, Inc. | Method of lyophilizing lipid nanoparticles |
| JP2024517427A (ja) * | 2021-04-20 | 2024-04-22 | アンジャリウム バイオサイエンシズ エージー | アミロ－α－１，６－グルコシダーゼ、４－α－グルカノトランスフェラーゼをコードするＤＮＡ分子の組成物、その作製の方法、及びその使用の方法 |
| CN118369335A (zh) * | 2022-01-06 | 2024-07-19 | 上海吉量医药工程有限公司 | N1位修饰假尿嘧啶核苷及其在mRNA合成中的应用 |
| CN115960926A (zh) * | 2022-12-30 | 2023-04-14 | 南方科技大学 | 一种mRNA及含有mRNA的药物 |
| EP4791878A1 (en) | 2023-10-13 | 2026-08-19 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating conditions associated with cartilage oligomeric matrix protein (comp) mutations |
| AU2024397279A1 (en) | 2023-12-13 | 2026-07-02 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating conditions associated with ube3a overexpression |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE291925T1 (de) | 2001-06-05 | 2005-04-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie |
| JP2006508939A (ja) | 2002-10-29 | 2006-03-16 | エンジーン， インコーポレイテッド | 癌処置のための組成物 |
| US8160205B2 (en) | 2004-04-06 | 2012-04-17 | Accuray Incorporated | Robotic arm for patient positioning assembly |
| PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| EP2049665A2 (en) | 2006-07-28 | 2009-04-22 | Applera Corporation | Dinucleotide mrna cap analogs |
| WO2009058911A2 (en) | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Preparation and isolation of 5' capped mrna |
| US9006191B2 (en) | 2007-12-27 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering RNA |
| EP3100718B1 (en) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
| EP2279254B1 (en) | 2008-04-15 | 2017-07-05 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
| US9050333B2 (en) | 2008-07-08 | 2015-06-09 | Duke University | Method of treating glycogen storage disease type III with human acid α-glucosidase |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| AU2009303345B2 (en) | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| WO2010048536A2 (en) | 2008-10-23 | 2010-04-29 | Alnylam Pharmaceuticals, Inc. | Processes for preparing lipids |
| EP3699172A3 (en) | 2008-11-10 | 2020-11-18 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
| EP2391343B1 (en) | 2009-01-29 | 2017-03-01 | Arbutus Biopharma Corporation | Improved lipid formulation for the delivery of nucleic acids |
| CA3042927C (en) | 2009-05-05 | 2022-05-17 | Arbutus Biopharma Corporation | Lipid compositions for the delivery of therapeutic agents |
| KR20220038506A (ko) | 2009-06-10 | 2022-03-28 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| SI2506857T1 (en) | 2009-12-01 | 2018-08-31 | Translate Bio, Inc. | Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases |
| EP4481047A3 (en) | 2010-06-03 | 2025-04-16 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| KR20220025112A (ko) | 2011-06-08 | 2022-03-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| DK3421601T3 (da) | 2011-12-30 | 2020-02-24 | Cellscript Llc | Fremstilling og anvendelse af in-vitro-syntetiseret ssRNA til indføring i pattedyrceller med henblik på at inducere en biologisk eller biokemisk effekt |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| US20150366997A1 (en) * | 2012-12-07 | 2015-12-24 | Shire Human Genetics Therapies, Inc. | COMPOSITIONS AND METHODS FOR mRNA DELIVERY |
| WO2014130722A1 (en) | 2013-02-20 | 2014-08-28 | Valerion Therapeutics, Llc | Methods and compositions for treatment of forbes-cori disease |
| WO2014164253A1 (en) | 2013-03-09 | 2014-10-09 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| US10266559B2 (en) | 2013-03-14 | 2019-04-23 | Translate Bio, Inc. | Ribonucleic acids with 4′-thio-modified nucleotides and related methods |
| EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| EP3574923A1 (en) | 2013-10-22 | 2019-12-04 | Translate Bio, Inc. | Mrna therapy for phenylketonuria |
| CN110003066B (zh) | 2013-11-18 | 2021-09-03 | 阿克丘勒斯治疗公司 | 用于rna递送的可电离的阳离子脂质 |
| EP3154570A4 (en) | 2014-06-13 | 2017-12-27 | Valerion Therapeutics, LLC | Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders |
| WO2016070166A2 (en) | 2014-11-02 | 2016-05-06 | Arcturus Therapeutics, Inc. | Messenger una molecules and uses thereof |
| EP3461904A1 (en) | 2014-11-10 | 2019-04-03 | ModernaTX, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
| EP4324473A3 (en) | 2014-11-10 | 2024-05-29 | ModernaTX, Inc. | Multiparametric nucleic acid optimization |
| US9709490B2 (en) | 2014-12-08 | 2017-07-18 | Canon Kabushiki Kaisha | Refractive index distribution measuring method, refractive index distribution measuring apparatus, and optical element manufacturing method |
| WO2017054086A1 (en) * | 2015-10-01 | 2017-04-06 | Exerkine Corporation | Treatment of genetic myopathies using bioengineered exosomes |
| WO2017100551A1 (en) | 2015-12-09 | 2017-06-15 | Alexion Pharmaceuticals, Inc. | HETEROLOGOUS UTR SEQUENCES FOR ENHANCED mRNA EXPRESSION |
| IL264439B2 (en) | 2016-08-17 | 2024-08-01 | Factor Bioscience Inc | non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment |
| KR20190093816A (ko) | 2016-10-26 | 2019-08-26 | 큐어백 아게 | 지질 나노입자 mRNA 백신 |
| US10526284B2 (en) | 2016-12-21 | 2020-01-07 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| US10383952B2 (en) | 2016-12-21 | 2019-08-20 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| US10227302B2 (en) | 2017-02-09 | 2019-03-12 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| KR102636537B1 (ko) * | 2017-05-31 | 2024-02-15 | 울트라제닉스 파마수티컬 인코포레이티드 | 글리코겐 축적 질환 유형 iii에 대한 치료제 |
-
2018
- 2018-05-31 KR KR1020197036416A patent/KR102636537B1/ko active Active
- 2018-05-31 WO PCT/US2018/035477 patent/WO2018222926A1/en not_active Ceased
- 2018-05-31 US US16/617,431 patent/US11377643B2/en active Active
- 2018-05-31 EP EP18810235.4A patent/EP3630964B1/en active Active
- 2018-05-31 MX MX2019014412A patent/MX2019014412A/es unknown
- 2018-05-31 CN CN201880036551.XA patent/CN110719954B/zh active Active
- 2018-05-31 JP JP2019565348A patent/JP7284101B2/ja active Active
- 2018-05-31 BR BR112019025224-0A patent/BR112019025224A2/pt unknown
- 2018-05-31 ES ES18810235T patent/ES3048960T3/es active Active
- 2018-05-31 TW TW107118693A patent/TWI794237B/zh active
- 2018-05-31 AU AU2018278315A patent/AU2018278315B2/en active Active
- 2018-05-31 AR ARP180101448A patent/AR112706A1/es unknown
-
2019
- 2019-11-27 CO CONC2019/0013332A patent/CO2019013332A2/es unknown
-
2022
- 2022-05-04 US US17/736,798 patent/US12703858B2/en active Active
-
2023
- 2023-03-13 JP JP2023038257A patent/JP2023075248A/ja active Pending